Framflyttad första handelsdag för Panion Animal Health

Panions aktie skulle enligt plan ha tagits upp till handel på Aktietorget den 16 juni 2017 men på grund av hög arbetsbelastning på Bolaget och intensiv aktivitet på aktiemarknaden har bolaget valt att senarelägga första dag för handel till slutet av juni. Bolaget återkommer inom kort med information om när handel i aktien inleds.

16 JUNI 2017

För mer information, kontakta:
Anja E. H. Holm, VD | + 45-22 94 66 00
anja.holm@panion-animalhealth.com

I juni 2015 bildade CombiGene ett helägt dotterbolag, som då hette CombiGene Vet AB, och i april 2016 beslutades att dela ut dotterbolaget till CombiGenes aktieägare med målet att notera bolaget. Fokus för bolaget, som nu namnändrats till Panion Animal Health AB, kommer att vara utnyttjandet av CombiGenes upptäckter för att utveckla en behandling av hundepilepsi. Panion kommer även att bedriva inlicensiering av andra projekt eller produkter inom animal health.

Panion Animal Health AB
Frykholmsgatan 11, 281 31 Hässleholm
info@panion-animalhealth.com

linkedin.com/company/panion-animalhealth
twitter.com/panionanihealth
panion-animalhealth.com/newsletter

panion-animalhealth.com

Nerladdningsbara filer

Panion at European Innovation Day

The European Medicines Agency (EMA) is the regulatory body that authorises biotechnological veterinary medicines in Europe. Thursday the 19.th of April 2018, the Agency held a well-visited day for businesses that work with innovative projects to keep them abreast with the current developments in authorisation requirements; the EMA veterinary medicines innovation day.




Panion expands the cooperation for the clinical development

With an agreement and contract that connects the well-reputed biostatistician Steve Radecki (USA)
to the coming clinical study in dogs with epilepsy, Panion's professional qualifications and competences are expanded. Clinical studies used for approval of medicines must be planned and evaluated with strict statistical methodology to ensure that the results are robust and significant. 


2017 Q4 report, October-December for Panion Animal Health

Period October-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -854 (-643).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

Period January-December

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -4 200 (-692).
  • Earnings per share: SEK -0,32 (-0,09).
  • Liquidity at the end of the period: kSEK 2 124 (306)

DRA contract ends & New advisory board member

Panion Animal Health AB's Director Regulatory Affairs, Niels-Erik Manniche, has decided to leave the company.


Panion enters into SEK 9,5 million financing and receives SEK 3 million in first tranche financing

Panion Animal Health AB (the "Company") has entered into a financing agreement with New York based Yorkville Advisors Global ("Yorkville") as the investment manager and on behalf of one or more of its investment funds has agreed to purchase up to SEK 9,000,000 of Convertible Notes of Panion Animal Health AB. In addition, Panion has entered into a financing agreement with Dividend Sweden who has agreed to purchase SEK 500,000 of convertible Notes of Panion Animal Health AB.


Panion's epilepsy product candidate for gene therapy in the dog: FDA has established an Investigational New Animal Drug (INAD) file.

Panion Animal Health AB ("Panion") has in Q4-17 requested the FDA to open an Investigational New Animal Drug application file to carry out the development of our new product for use in the dog. Panion plans to develop and gain approval for the use of CG-01-canine, a recombinant adeno-associated virus vector expressing neuropeptide Y and receptor peptide Y2 to treat drug refractory idiopathic epilepsy in the dog via intracranial injection.


New CFO in Panion, Sofia Josephson

Panion Animal Health AB has had a very satisfactory cooperation with our CFO Anni Acs, who excellently handled the business transition into the stock market, shares issue, and daily financial controlling. Anni has moved to a new job challenge and we wish her all the best.


Panion's epilepsy product classified as MUMS in EU for dogs and cats

Panion Animal Health AB has received the European Medicines Agency's acceptance of the classification as MUMS (Minor Use Minor Species) for our epilepsy product for both dogs and cats. The request for classification was submitted to the Committee for Medicinal Products for Veterinary Use (CVMP) in the European Medicines Agency (EMA) earlier in 2017 and has now been successfully evaluated. 


Följ oss

Om beQuoted

beQuoted publicerar nyheter, analyser och pressmeddelanden för investerare och journalister. Viktiga företagshändelser bevakas av vår egen nyhetsredaktion och vidaredistribueras i ledande finansiella medier.

Vi uppdaterar även nyhetsrum, Investor Relations och IR-webbplatser för företag som vill utveckla sina relationer med finansmarknaden.

Kontakta oss

beQuoted AB
Sturegatan 32
114 36 Stockholm

08-692 21 90
Kontaktformulär

Kontakta oss

Vill du veta mer om beQuoted och våra tjänster så fyll i nedanstånde uppgifter och tryck skicka.

En av våra rådgivare kontaktar dig inom kort.

Namn: Telefon: E-postadress: Meddelande: